Recursion's share price has dropped in recent weeks due to poor clinical trial data, but its most mature assets are not reflective of its current capabilities. Recursion probably needs to advance 5-10 ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する